Durvalumab extends survival in small cell lung cancer while raising critical cost‑effectiveness concerns
Durvalumab improves survival in limited‑stage small cell lung cancer (LS‑SCLC) but its cost‑effectiveness is not favorable in the United States.
Bizonyítékszint: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Kapcsolódó jelek
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells